Study: UVA heart failure program improves survival, reduces costs

July 31, 2018

A University of Virginia Health System program that provides follow-up care for heart failure patients after they leave the hospital significantly improves survival and other outcomes while saving money, a new study finds.

The study examined participants between January 2011 and December 2014 in UVA's Hospital-to-Home (H2H) program, which is available to all heart failure patients that live within 90 miles of UVA Medical Center. For 30 days after they are released from the hospital, patients can have follow-up visits and other support from two nurse practitioners specializing in heart failure.

In the first 30 days after being released from UVA, program participants had a 41 percent lower mortality rate and a 24 percent reduction in the number of days they were readmitted to the hospital compared with patients that did not participate in the H2H program during this timeframe. These improvements in outcomes occurred even though H2H participants were sicker than non-participants, the study found.

The cost savings from the program were estimated to be about twice as much as the program's staffing costs. This is especially valuable because other studies have shown that heart failure care - which cost an estimated $31.7 billion in 2012 and is projected to more than double by 2030 - is a leading driver of healthcare costs in the U.S.

Keys to Success

Because heart failure is a chronic disease, ongoing management of each patient's care is key to good outcomes, said Sula Mazimba, MD, MPH, a study co-author and a heart failure specialist at UVA.

"It's important to have a program that follows patients closely and especially during their most vulnerable period following a discharge from the hospital. In this regard, a discharge from the hospital is not really a final goodbye, but rather just another phase of their care," he said.

Within a week of being released from the hospital, patients typically have an in-person visit with one of the program's nurse practitioners. Working with UVA physicians, pharmacists and other team members, the nurse practitioners assess patients' heart failure symptoms and lab results, adjust their medications as needed and suggest lifestyle adjustments such as dietary changes.

"It's a collaborative, multidisciplinary approach," said study co-author Kenneth Bilchick, MD, MS, a member of UVA's heart and vascular team. "We take a holistic view of what needs to be done to keep patients out of the hospital."
-end-
Findings Published

Bilchick, Mazimba and their colleagues have published their findings in the American Journal of Medical Quality. Their research team consisted of Travis Moss, Timothy Welch, Wayne Levy (University of Washington), George Stukenborg, Bryan T. Lawlor, Juanita Reigle, S. Craig Thomas, Carolyn Brady, James D. Bergin, Jamie L.W. Kennedy, Mohammed Abuannadi and Kenneth Scully.

University of Virginia Health System

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.